| ■ | Oral presentation at the Digestive Disease Week 2023 featured positive clinical data showing a reduction of 33% in incomplete bowel prep (IBP)in just six months after implementation of the Pure-Vu® system at the Minneapolis VA Medical Center | |
| ■ | The Company is advancing its development of Pure-Vu EVS Gastro, designed for Upper GI bleeding procedures - an area of high unmet patient need - and expects submission of the 510(k) to the FDA for this new product line and its next generation Lower GI platform in Q4 2023 | |
| ■ | The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value |
FORT LAUDERDALE, Fla., May 10, 2023 (GLOBE NEWSWIRE) --Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the first quarter ended March 31, 2023, and provided a corporate update.
“We continue to advance the development of several potential growth drivers for our business, including R&D efforts to bring Pure-Vu Upper GI, and an enhanced Lower GI platform to market. The planned 510(k) submission to the FDA for the Pure-Vu Gastro Upper GI system and advancements to the overall platform remains on track for the fourth quarter of 2023,” commented Mark Pomeranz, Chief Executive Officer. “While our Pure-Vu technology makes up the backbone of these two new devices, each product provides significant improvements and are designed to potentially open significant new segments of the GI market by introducing new capabilities while also addressing factors that make it easier to work with commercial partners, including minimizing training requirements and reducing the cost of goods by approximately 50%.”
First Quarter and Recent Business Highlights
| ■ | Data showing an improved rate of incomplete bowel prep (IBP) after implementation of the Pure-Vu® system at the Minneapolis VA Medical Center (MVA) was selected for an oral presentation during the Digestive Disease Week in May 2023. The data show that six months after the implementation of the Pure-Vu system, MVA noted a lowered rate of IBP by 33% hospital wide to 5.9% compared with 9.3% for the six months prior to implementation of the device, reducing canceled and early repeat procedures, as well as improving examination quality and resource utilization. | ||||
| ■ | The Company continues to advance the development of the Pure-Vu EVS Gastro device, which is on track to be submitted to the FDA via the 510(k) process before the end of this year. This device brings upper GI capabilities to the new Pure-Vu EVS platform through key enhancements, including a larger and more powerful suction channel, more efficient irrigation jets, and a smaller profile distal tip that offers enhanced flexibility during insertion. In addition, several of the design enhancements are expected to result in a significant reduction in cost-of-goods. The Company believes the Upper GI application and removing adherent blood clots from the field of view is a significant need in allowing a physician the ability to identify and treat a GI bleed in a patient populational with high mortality rate of ~13% | ||||
| ■ | The Company is working on incorporating the improvements developed for the Pure-Vu EVS Gastro into the device for the colon. These enhancements are expected to achieve a reduction in the cost-of-goods of approximately 50% and reduce the training requirements for both the sales team and the customer. These improvements along with the Pure-Vu EVS Gastro should better position the company for strategic relationships with the goal to maximizing stockholder value and accelerate commercialization of the Pure-Vu System, however, there can be no assurance that it will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful | ||||
| ■ | The Company continues to provide sales support and service to hospitals across the United States that have implemented Pure-Vu EVS and is focused on adding targeted new pipeline opportunities in contracted health systems. These efforts include building the Company’s relationship with the Veterans Health Administration (VHA), the largest integrated health care system in the U.S. Several VA hospitals have already implemented Pure-Vu EVS and Motus is currently working with additional VA hospitals to include Pure-Vu EVS in their 2024 budget planning and leveraging Motus GI’s official position as a sole source provider and small business by the VHA. | ||||
| ■ | To date in 2023, the Company has announced two rounds of cost-cutting measures which are expected to reduce operating expense cash burn by more than 50% in order to aggressively preserve capital. The primary cuts are attributable to reductions in the Company’s executive management, workforce, and clinical expenses. The Company expects to incur certain non-recurring charges related to these cost-cutting measures of approximately $1.5 million in the first half of 2023. | ||||
Financial Results for the Quarter Ended March 31, 2023
The Company reported revenue of $56,000 for the first quarter 2023, compared to $20,000 for the same period last year. Revenues for this past quarter were primarily derived from reorders and new customer orders of disposable sleeves.
For the three months ended March 31, 2023, the Company reported a net loss attributable to common shareholders of $4.4 million, or $0.92 per basic and diluted share, which includes the impact of restructuring charges of $1.3 million related to the first quarter strategic restructuring program. This is comparable to a net loss attributable to common shareholders of $4.8 million, or $1.86 per basic and diluted share, for the same period last year.
During the first quarter 2023, net cash used in operating activities and for the purchase of fixed assets was $4.8 million compared to $5.2 million for the same period of 2022.
The Company reported $8.6 million in cash and cash equivalents as of March 31, 2023. This balance included the fully funded credit facility with Kreos Capital, which has approximately $10.6 million due and outstanding.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, risks related to the continued impact of the COVID-19 pandemic, risks inherent in the development and commercialization of potential products, possible or assumed future results of operations, business strategies, potential grow opportunities, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s quarterly and annual reports filed with the Securities and Exchange Commission, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
Troy Williams
LifeSci Advisors
(518) 221-0106
This email address is being protected from spambots. You need JavaScript enabled to view it.
Motus GI Holdings, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited, in thousands, except share and per share amounts)
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 8,648 | $ | 14,042 | ||||
| Accounts receivable | 52 | 59 | ||||||
| Inventory, current | 464 | 488 | ||||||
| Prepaid expenses and other current assets | 1,093 | 781 | ||||||
| Total current assets | 10,257 | 15,370 | ||||||
| Fixed assets, net | 1,237 | 1,325 | ||||||
| Inventory, non-current | 334 | 511 | ||||||
| Right-of-use assets | 390 | 428 | ||||||
| Other non-current assets | 13 | 13 | ||||||
| Total assets | $ | 12,231 | $ | 17,647 | ||||
| Liabilities and Shareholders’ (Deficiency) Equity | ||||||||
| Current liabilities: | ||||||||
| Current portion of long-term debt, net of unamortized debt discount of $168 and $182, respectively | $ | 2,611 | $ | 2,532 | ||||
| Accounts payable and accrued expenses | 1,472 | 1,969 | ||||||
| Operating lease liabilities - current | 248 | 245 | ||||||
| Other current liabilities | 47 | 53 | ||||||
| Total current liabilities | 4,378 | 4,799 | ||||||
| Convertible note, net of unamortized debt discount of $94 and $108, respectively | 3,906 | 3,892 | ||||||
| Long-term debt, net of unamortized debt discount of $104 and $135, respectively | 3,904 | 4,589 | ||||||
| Contingent royalty obligation | 992 | 1,212 | ||||||
| Operating lease liabilities - non-current | 136 | 178 | ||||||
| Total liabilities | 13,316 | 14,670 | ||||||
| Commitments and contingent liabilities (Note 9) | ||||||||
| Shareholders’ (deficiency) equity | ||||||||
| Common stock $0.0001 par value;115,000,000 shares authorized; 4,778,873 and 4,659,769 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively | - | - | ||||||
| Additional paid-in capital | 144,652 | 144,328 | ||||||
| Accumulated deficit | (145,737 | ) | (141,351 | ) | ||||
| Total shareholders’ (deficiency) equity | (1,085 | ) | 2,977 | |||||
| Total liabilities and shareholders’ (deficiency) equity | $ | 12,231 | $ | 17,647 | ||||
Motus GI Holdings, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited, in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Revenue | $ | 56 | $ | 20 | ||||
| Operating expenses: | ||||||||
| Cost of revenue - sales | 9 | 15 | ||||||
| Cost of revenue - impairment of inventory | 165 | 159 | ||||||
| Research and development | 1,454 | 1,275 | ||||||
| Sales and marketing | 842 | 983 | ||||||
| General and administrative | 1,945 | 2,114 | ||||||
| Total costs and expenses | 4,415 | 4,546 | ||||||
| Loss from Operations | (4,359 | ) | (4,526 | ) | ||||
| Gain on change in estimated fair value of contingent royalty obligation | 220 | 29 | ||||||
| Finance expense, net | (239 | ) | (332 | ) | ||||
| Foreign currency (loss) gain | (8 | ) | 18 | |||||
| Net loss | $ | (4,386 | ) | $ | (4,811 | ) | ||
| Basic and diluted loss per common share: | $ | (0.92 | ) | $ | (1.86 | ) | ||
| Weighted average number of common shares outstanding, basic and diluted | 4,763,210 | 2,589,712 | ||||||
| Last Trade: | US$0.00 |
| Daily Change: | -0.17 -100.00 |
| Daily Volume: | 6,900 |
March 18, 2024 February 22, 2024 February 21, 2024 November 13, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
